Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. No Reliable Association between Runs of Homozygosity and Schizophrenia in a Well-Powered Replication Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Leveraging Genomic Annotations and Pleiotropic Enrichment for Improved Replication Rates in Schizophrenia GWAS

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. An Empirical Bayes Mixture Model for Effect Size Distributions in Genome-Wide Association Studies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The molecular profile of mucosal melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The current epidemic of HPV-associated oropharyngeal cancer: An 18-year Danish population-based study with 2,169 patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Estimating narrow-sense heritability using family data from admixed populations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Fergus J Couch
  • Xianshu Wang
  • Lesley McGuffog
  • Andrew Roger Lee
  • Curtis Olswold
  • Karoline B Kuchenbaecker
  • Penny Soucy
  • Zachary Fredericksen
  • Daniel Barrowdale
  • Joe Dennis
  • Mia M Gaudet
  • Ed Dicks
  • Matthew Kosel
  • Sue Healey
  • Olga M Sinilnikova
  • Adam Lee
  • François Bacot
  • Daniel Vincent
  • Frans B L Hogervorst
  • Susan Peock
  • Dominique Stoppa-Lyonnet
  • Anna Jakubowska
  • Paolo Radice
  • Rita Katharina Schmutzler
  • Susan M Domchek
  • Marion Piedmonte
  • Christian F Singer
  • Eitan Friedman
  • Mads Thomassen
  • Thomas V O Hansen
  • Susan L Neuhausen
  • Csilla I Szabo
  • Ignacio Blanco
  • Mark H Greene
  • Beth Y Karlan
  • Judy Garber
  • Catherine M Phelan
  • Jeffrey N Weitzel
  • Marco Montagna
  • Edith Olah
  • Irene L Andrulis
  • Andrew K Godwin
  • Drakoulis Yannoukakos
  • David E Goldgar
  • Trinidad Caldes
  • Anne-Marie Gerdes
  • Bent Ejlertsen
  • Finn C Nielsen
  • Lars Jønson
  • Mette K Andersen
  • kConFab Investigators
Vis graf over relationer
BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further cancer risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with breast and 1,839 were diagnosed with ovarian cancer), with a further replication in an additional sample of 2,646 BRCA1 carriers. We identified a novel breast cancer risk modifier locus at 1q32 for BRCA1 carriers (rs2290854, P = 2.7 × 10(-8), HR = 1.14, 95% CI: 1.09-1.20). In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4 × 10(-8), HR = 1.27, 95% CI: 1.17-1.38) and 4q32.3 (rs4691139, P = 3.4 × 10(-8), HR = 1.20, 95% CI: 1.17-1.38). The 4q32.3 locus was not associated with ovarian cancer risk in the general population or BRCA2 carriers, suggesting a BRCA1-specific association. The 17q21.31 locus was also associated with ovarian cancer risk in 8,211 BRCA2 carriers (P = 2×10(-4)). These loci may lead to an improved understanding of the etiology of breast and ovarian tumors in BRCA1 carriers. Based on the joint distribution of the known BRCA1 breast cancer risk-modifying loci, we estimated that the breast cancer lifetime risks for the 5% of BRCA1 carriers at lowest risk are 28%-50% compared to 81%-100% for the 5% at highest risk. Similarly, based on the known ovarian cancer risk-modifying loci, the 5% of BRCA1 carriers at lowest risk have an estimated lifetime risk of developing ovarian cancer of 28% or lower, whereas the 5% at highest risk will have a risk of 63% or higher. Such differences in risk may have important implications for risk prediction and clinical management for BRCA1 carriers.
OriginalsprogEngelsk
TidsskriftP L o S Genetics (Online)
Vol/bind9
Udgave nummer3
Sider (fra-til)e1003212
ISSN1553-7404
DOI
StatusUdgivet - 2013

ID: 42317649